3-甲氧基-4-甲基苯异丙胺 | 141231-59-6

• 分子结构分类: 有机化合物 - 有机聚合物 - 多肽
• 中文名称: 3-甲氧基-4-甲基苯异丙胺
• 英文名称: Substance P, N-spermine-gln(5)-
• 英文别名: (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-[3-[4-(3-aminopropylamino)butylamino]propylamino]-5-oxopentanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[2-[[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]pentanediamide
• CAS: 141231-59-6
• 化学式: C₇₃H₁₂₁N₂₁O₁₃S
• 分子量: 1532.96
• InChiKey: XMQKJEXWKUHJIE-PVGXKDMPSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  108
• 可旋转键数：
  54
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  581
• 氢给体数：
  18
• 氢受体数：
  20

反应信息

• 作为产物：
  描述：

  精胺 、 多肽物质P 在 谷氨酰胺转移酶 作用下， 以 various solvent(s) 为溶剂， 反应 18.0h， 生成 3-甲氧基-4-甲基苯异丙胺
  参考文献：
  名称：

  Transglutaminase-synthesized spermine derivative of substance P recognizes rat portal vein neurokinin-3 receptors

  摘要：

  The effects of the transglutaminase-sinthesized polyamine derivatives of Substance P (SP) have been further characterized by their ability to contract in vitro the rat portal vein strip (RPV), a pharmacological preparation particularly rich in NK-3 receptors. The effects of selective agonists of NK-1, NK-2 and NK-3 receptors [Sar(9),Met(O-2)(11)]SP beta-Ala(8) NKA(4-10),and senktide respectively, were also evaluated by measuring RPV concentration-response curves. Peptide [GR-82334 (NK-1) and MEN-10,376 (NK-2)] and nonpeptide [WIN 51,708 (NK-1) and SR 142801 (NK-3)] NK receptor antagonists were used to confirm the participation of the different NK receptors to contractile response. Our results demonstrated that the spermine derivative of SP (Spm-SP), previously shown to be unable to recognize NK-1 and NK-2 receptors in some bioassays, contracts RPV (EC(50) = 588 nM) better than the native neuropeptide (EC(50) = 1120 nM). A pretreatment with thiorphan, an inhibitor of neutral endopeptidases, significantly reduced such a difference. While this inhibitor shifts the SP concentration-response curves to the left (EC(50) = 720 nM) the action of Spm-SP and [Sar(9),Met(O-2)11]SP were completely thiorphan-resistant. In the absence of thiorphan we found the following rank order of potency: senktide>>beta-Ala(8) NKA(4-1O)>[Sar9,Met(O-2)(11)]SP=Spm-SP>SP. Among the mentioned NK receptor antagonists, only the selective NK-3 receptor antagonist, SR 142801, shifted to the right Spm-SP and [Sar(9),Met(O-2)(11)]SP concentration-response curve, showing pK(B) values of 5.84 and 5.88, respectively. Therefore, the reported results suggest that the introduction of a Spm moiety into the SP alters the parent peptide molecule by increasing its affinity for NK-3 receptors and/or by preventing its degradation by some proteolytic enzymes.

  DOI：

  10.1016/s0024-3205(96)00665-0

文献信息

• Transglutaminase-synthesized spermine derivative of substance P recognizes rat portal vein neurokinin-3 receptors
  作者：A. Filippelli、C. Esposito、M. Falciani、C. Costa、A. Cozzolino、F. Rossi、R. Porta

  DOI：10.1016/s0024-3205(96)00665-0

  日期：1997.1

  The effects of the transglutaminase-sinthesized polyamine derivatives of Substance P (SP) have been further characterized by their ability to contract in vitro the rat portal vein strip (RPV), a pharmacological preparation particularly rich in NK-3 receptors. The effects of selective agonists of NK-1, NK-2 and NK-3 receptors [Sar(9),Met(O-2)(11)]SP beta-Ala(8) NKA(4-10),and senktide respectively, were also evaluated by measuring RPV concentration-response curves. Peptide [GR-82334 (NK-1) and MEN-10,376 (NK-2)] and nonpeptide [WIN 51,708 (NK-1) and SR 142801 (NK-3)] NK receptor antagonists were used to confirm the participation of the different NK receptors to contractile response. Our results demonstrated that the spermine derivative of SP (Spm-SP), previously shown to be unable to recognize NK-1 and NK-2 receptors in some bioassays, contracts RPV (EC(50) = 588 nM) better than the native neuropeptide (EC(50) = 1120 nM). A pretreatment with thiorphan, an inhibitor of neutral endopeptidases, significantly reduced such a difference. While this inhibitor shifts the SP concentration-response curves to the left (EC(50) = 720 nM) the action of Spm-SP and [Sar(9),Met(O-2)11]SP were completely thiorphan-resistant. In the absence of thiorphan we found the following rank order of potency: senktide>>beta-Ala(8) NKA(4-1O)>[Sar9,Met(O-2)(11)]SP=Spm-SP>SP. Among the mentioned NK receptor antagonists, only the selective NK-3 receptor antagonist, SR 142801, shifted to the right Spm-SP and [Sar(9),Met(O-2)(11)]SP concentration-response curve, showing pK(B) values of 5.84 and 5.88, respectively. Therefore, the reported results suggest that the introduction of a Spm moiety into the SP alters the parent peptide molecule by increasing its affinity for NK-3 receptors and/or by preventing its degradation by some proteolytic enzymes.